Spotlight

Xerava has been developed for the treatment of cIAI in patients 18 years of age and older. In clinical trials, Xerava has showed statistical non-inferiority to two widely

The partnership will assess Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy in a phase 2 study in patients with metastatic triple negative breast cancer (TNBC). The trial has been

The approval follows the priority review of Alecensa in China, just eight and nine months after European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approvals,

The partnership will carry out clinical trial to explore the potential of combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent alvocidib to treat relapsed/refractory AML. Alvocidib is

Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases, and to help ensure people have access to

The Series C round was led by Deerfield Management while RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors and others made significant new investments in the gene therapy

Spark Therapeutics reported that although most of the patients could have their bleeding reduced by its gene therapy, one participant though did not quickly respond to oral steroids. The

The company will pay the amount to clear two whistleblower lawsuits brought by the state of Texas under the Texas Medicaid Fraud Prevention Act (TMFPA). Under the first

Cystic fibrosis (CF) is characterized by abnormal ion transport in the apical membrane of epithelial cells. The partnership will use a novel and replication deficient lentiviral vector in